Membranous glomerulonephritis
Introduction
Epidemiology
- Incidence: 2.00 cases per 100,000 person-years
- Peak incidence: 50-60 years
- Sex ratio: 1:1
<1 | 1-5 | 6+ | 16+ | 30+ | 40+ | 50+ | 60+ | 70+ | 80+ |
Aetiology
- idiopathic: due to anti-phospholipase A2 antibodies
- infections: hepatitis B, malaria, syphilis
- malignancy: lung cancer, lymphoma, leukaemia
- drugs: gold, penicillamine, NSAIDs
- autoimmune diseases: systemic lupus erythematosus (class V disease), thyroiditis, rheumatoid
Clinical features
- Low albumin (50%)
- Non-visible haematuria (50%)
- Facial swelling (40%)
- Hypertension (10%)
- Nephrotic syndrome (80%)
- Weight gain (20%)
- Bilateral distal leg swelling (20%)
- Proteinuria (95%)
- Swelling around the eye (60%)
Investigations
- electron microscopy: the basement membrane is thickened with subepithelial electron dense deposits. This creates a 'spike and dome' appearance
Management
- all patients should receive an ACE inhibitor or an angiotensin II receptor blocker (ARB):
- these have been shown to reduce proteinuria and improve prognosis
- immunosuppression
- as many patients spontaneously improve only patient with severe or progressive disease require immunosuppression
- corticosteroids alone have not been shown to be effective. A combination of corticosteroid + another agent such as cyclophosphamide is often used
- consider anticoagulation for high-risk patients
Prognosis
- one-third: spontaneous remission
- one-third: remain proteinuric
- one-third: develop ESRF
Good prognostic features include female sex, young age at presentation and asymptomatic proteinuria of a modest degree at the time of presentation.